RecruitingPhase 1NCT06383338

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.

A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.

Sponsor

Murdoch Childrens Research Institute

Enrollment

10 participants

Start Date

Jul 22, 2025

Study Type

INTERVENTIONAL

Conditions

Hodgkin Lymphoma Non-Hodgkin Lymphoma

Summary

PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers. The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications. The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.

Eligibility

Min Age: 6 YearsMax Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how the body's metabolism changes during treatment for lymphoma (a blood cancer) in young people. Researchers will use small test doses of common drugs to measure how well the body processes medications, which could help personalize treatment in the future. **You may be eligible if...** - You are between 6 and 25 years old - You have just been diagnosed with Hodgkin or Non-Hodgkin Lymphoma for the first time - You can swallow or receive medication through a feeding tube - You or your guardian can provide written consent **You may NOT be eligible if...** - You have previously had cancer treatment - You have a known allergy to omeprazole (a heartburn medication) or dextromethorphan (a cough medication) - You have severe organ problems (liver, kidney, or gut failure) - Your condition requires urgent treatment before study staff can get consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.